BBIO shorts ease as activists trim and analysts split on target

BridgeBio Pharma enters the week with an interesting tension: short sellers hold a meaningful 10.6% of the free float, yet that position has been quietly shrinking while the stock has gained 6.7% over the past five days to close at $67.55.

Short interest has pulled back roughly 6% over the past month, from around 23.4 million shares in early September to 20.5 million now. The decline has been steady rather than dramatic. Borrow costs have eased alongside it, dropping more than 20% over the past month to just 0.48%, a low level that signals no urgency among new short sellers. Availability is extremely loose at 890%, meaning nearly nine shares remain available for every one already borrowed. That combination, falling short interest, cheap borrow, and ample supply, describes a short base that is gradually unwinding rather than one building toward a squeeze. Options positioning reinforces this: the put/call ratio is 0.18, well below its 20-day average of 0.33, near the lowest reading of the past year. Call volume is dominating, reflecting a more bullish tilt in the derivatives market right now.

Analyst opinion has been active this week and is more divided than the consensus might suggest. Morgan Stanley maintained its Overweight rating but cut its target from $97 to $87, citing concerns the market has not yet resolved. Citigroup, which holds a Neutral view, trimmed its target modestly to $91 from $94. Against that, Piper Sandler raised its target to $120 from $115 while keeping Overweight, and UBS assumed coverage with a Buy and a $92 target last week. The mean analyst target across the Street sits at $108, implying roughly 60% upside from the current price. That gap reflects genuine disagreement: bulls point to Attruby's commercial momentum, with Q2 US sales of $222 million up 23% sequentially and 211% year over year, plus a pipeline of late-stage catalysts including encaleret and BBP-418. Bears focus on the balance sheet, roughly $1.9 billion in debt against $720 million in cash at the end of Q2, and the competitive pressure Pfizer's tafamidis franchise continues to exert in the ATTR-CM market. The company's forward earnings trajectory scores well on the ORTEX factor model, with the 12-month forward EPS improvement ranking in the 86th percentile, and analyst recommendation momentum in the 92nd. But the short score rank, at the 24th percentile, and a deeply negative price-to-book multiple reflect how much of the investment case still rests on execution ahead.

Two activists are on the register, and both have been reducing. Viking Global Investors filed a Schedule 13D/A in July, disclosing its stake had fallen from 6.1% to 5.0%. KKR filed a 13D/A in August showing a sharper reduction, from 7.0% to 4.7%. Both originally filed as activists, the higher-signal 13D designation rather than the passive 13G form, which makes their trimming worth noting. Stakes are as last disclosed and holders falling below 5% may not file again, so actual current positions could differ. Janus Henderson remains the largest institutional holder at 7.2% of shares, and Wellington Management added 2.8 million shares as of August, moving in the opposite direction to the two activists.

On BridgeBio's own real-economy data, Medicaid reimbursement figures from the Centers for Medicare and Medicaid Services show both dollars reimbursed and units reimbursed have risen for three consecutive quarters, with the most recent reading at $1.5 million reimbursed for the period ending January 2026. The trend is directionally consistent with the commercial story the company has been telling, though none of the available datasets has been measured to lead BridgeBio's reported financials. Retail attention has also picked up sharply, with a Wikipedia and ORTEX page-view signal running at a z-score of 4.1 relative to the past 90 days, the highest in recent history.

Earnings are due October 30. The last print, in August, produced a 0.9% one-day decline and a 5.4% five-day decline. The print before that, in May, produced a 2.3% one-day gain followed by a 3.6% five-day slide. The pattern across both events is a muted immediate reaction that then drifted lower over the following week. With Morgan Stanley cutting its target hours before today's close and the stock already up sharply on the week, how the market interprets Q3 Attruby sales and any update on the pipeline timeline is the number to watch on October 30.